Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
SEK 0.04
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders,...
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is 'cheap' on EV/EBITDA.
Data is available to registered users only
Buy
Sell